Cabaletta Bio (CABA) Free Cash Flow (2018 - 2025)
Cabaletta Bio (CABA) posted quarterly Free Cash Flow of -$35.3 million for Q4 2025, down 50.41% year-over-year from -$71.3 million in Q4 2024, and down 2.54% quarter-over-quarter from -$34.5 million in Q3 2025.
Powered by 
Analysis
Cabaletta Bio (CABA) Free Cash Flow (2018 - 2025) Analysis & Trends
Cabaletta Bio's Free Cash Flow history runs 8 years deep, the most recent figure standing at -$35.3 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 50.41% year-over-year to -$35.3 million; the TTM figure through Dec 2025 stood at -$131.1 million (down 44.95% YoY), while the FY2025 annual figure was -$131.1 million, down 44.95% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$35.3 million, down from -$34.5 million in the prior quarter.
- The five-year high for Free Cash Flow was -$7.0 million in Q2 2021, with the low at -$35.3 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$13.0 million (2022), against an average of -$17.9 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow increased 13.88% in 2022, then plunged 95.51% in 2024.
- Cabaletta Bio's Free Cash Flow stood at -$11.6 million in 2021, then rose by 13.88% to -$10.0 million in 2022, then tumbled by 66.58% to -$16.6 million in 2023, then sank by 41.15% to -$23.5 million in 2024, then plunged by 50.41% to -$35.3 million in 2025.
- Business Quant data shows CABA's Free Cash Flow at -$35.3 million in Q4 2025, -$34.5 million in Q3 2025, and -$29.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -35.55 Mn |
| Sep 30, 2025 | -34.59 Mn |
| Jun 30, 2025 | -30.59 Mn |
| Mar 31, 2025 | -31.59 Mn |
| Dec 31, 2024 | -23.50 Mn |
| Sep 30, 2024 | -20.58 Mn |
| Jun 30, 2024 | -21.56 Mn |
| Mar 31, 2024 | -24.80 Mn |
| Dec 31, 2023 | -16.65 Mn |
| Sep 30, 2023 | -12.67 Mn |
| Jun 30, 2023 | -11.95 Mn |
| Mar 31, 2023 | -12.99 Mn |
| Dec 31, 2022 | -12.45 Mn |
| Sep 30, 2022 | -11.01 Mn |
| Jun 30, 2022 | -12.42 Mn |
| Mar 31, 2022 | -12.96 Mn |
| Dec 31, 2021 | -10.67 Mn |
| Sep 30, 2021 | -8.84 Mn |
| Jun 30, 2021 | -6.72 Mn |
| Mar 31, 2021 | -9.05 Mn |